A

Ayr Wellness Inc
CNSX:AYR.A

Watchlist Manager
Ayr Wellness Inc
CNSX:AYR.A
Watchlist
Price: 0.155 CAD Market Closed
Market Cap: CA$18.1m

Relative Value

There is not enough data to reliably calculate the relative value of AYR.A.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AYR.A Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

AYR.A Competitors Multiples
Ayr Wellness Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Ayr Wellness Inc
CNSX:AYR.A
17.7m CAD 0 -0 7.3 -10.1
US
Eli Lilly and Co
NYSE:LLY
1.1T USD 17.7 57 38.2 41
US
Johnson & Johnson
NYSE:JNJ
564.7B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
287.9B CHF 4.7 30.7 12.9 15.1
US
Merck & Co Inc
NYSE:MRK
294.9B USD 4.6 15.5 10.9 12.9
CH
Novartis AG
SIX:NOVN
229.6B CHF 5.3 20.5 12.9 16.6
UK
AstraZeneca PLC
LSE:AZN
215B GBP 5.1 31.6 15.1 22.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.6
US
Pfizer Inc
NYSE:PFE
153.2B USD 2.4 15.6 7.8 10.7
FR
Sanofi SA
PAR:SAN
98.9B EUR 1.8 8.3 7.7 7.7
P/E Multiple
Earnings Growth PEG
US
A
Ayr Wellness Inc
CNSX:AYR.A
Average P/E: 23.7
Negative Multiple: -0
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
57
54%
1.1
US
Johnson & Johnson
NYSE:JNJ
21.1
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.7
29%
1.1
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
17%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.6
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
2%
6.6
US
Pfizer Inc
NYSE:PFE
15.6
27%
0.6
FR
Sanofi SA
PAR:SAN
8.3
1%
8.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Ayr Wellness Inc
CNSX:AYR.A
Average EV/EBITDA: 42.7
7.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
US
Merck & Co Inc
NYSE:MRK
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
12.9
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
1%
9.2
US
Pfizer Inc
NYSE:PFE
7.8
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Ayr Wellness Inc
CNSX:AYR.A
Average EV/EBIT: 99
Negative Multiple: -10.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
18
6%
3
CH
Roche Holding AG
SIX:ROG
15.1
6%
2.5
US
Merck & Co Inc
NYSE:MRK
12.9
8%
1.6
CH
Novartis AG
SIX:NOVN
16.6
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
0%
N/A
US
Pfizer Inc
NYSE:PFE
10.7
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3